Evidence map›Paper›PMID 35411158›Full record

ArticleInfection and drug resistance2022

Emergence of a Multidrug-Resistant

Danni Bao, Xiaohong Xu, Yizhang Wang, Fengjiao Zhu

Abstract read
In one paragraph

Article in Infection and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Characteristics ofOne health (Amsterdam, Netherlands) · 2026
    Article
  2. Genomic Characteristics of a Carbapenem-ResistantInfection and drug resistance · 2026
    Article
  3. Molecular characterization ofFrontiers in veterinary science · 2025
    Article
  4. Plasmid-Mediated Co-Occurrence ofTransboundary and emerging diseases · 2024
    Article
  5. Article
  6. First report ofFrontiers in microbiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Danni BaoDepartment of Clinical Laboratory, Sanmen People's Hospital, Taizhou, Zhejiang, People's Republic of China.
Xiaohong XuDepartment of Clinical Laboratory, Sanmen People's Hospital, Taizhou, Zhejiang, People's Republic of China.
Yizhang WangDepartment of Clinical Laboratory, Sanmen People's Hospital, Taizhou, Zhejiang, People's Republic of China.
Fengjiao ZhuDepartment of Clinical Laboratory, Sanmen People's Hospital, Taizhou, Zhejiang, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Carbapenem-resistant Enterobacterales (CRE) are a significant threat to worldwide public health, resulting in increased morbidity, death, hospitalization time and healthcare expenses. Here, the genomic and phylogenetic characteristics of a multidrug-resistant Methods: Antimicrobial susceptibility of Results: Conclusion: We discovered the first multidrug-resistant ST101

Indexed as

blaNDM-5Escherichia colimcr-1.33multidrug-resistanceurinary tract infectionwhole genome sequencing

Identifiers

PMID35411158
PMCPMC8994605

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.